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	 2	To	the	editor:	Addition	of	the	CD33-targeted	immunoconjugate	gemtuzumab	ozogamicin	(GO;	Pfizer,	New	York,	USA)	has	been	shown	to	improve	the	response	to	standard	induction	chemotherapy	and	results	in	better	long-term	survival	in	adult	patients	with	acute	myeloid	leukemia	(AML).1	The	greatest	impact	was	observed	in	those	with	favorable-risk	cytogenetics,	with	a	lesser	but	still	significant	benefit	in	patients	with	intermediate-risk	cytogenetics	but	no	benefit	in	those	with	adverse-risk	cytogenetics.1	Several	studies	have	also	demonstrated	that	the	response	positively	correlates	with	higher	levels	of	membrane	CD33	expression	on	leukemic	blasts.2-5	Data	recently	published	by	Lamba	and	colleagues	further	suggests	that	genotype	at	a	common	single	nucleotide	polymorphism	(SNP)	in	the	CD33	gene	(rs12459419	C>T)	determines	response	to	GO	in	patients	aged	0-29	years	with	de	novo	AML	treated	on	the	randomized	phase	III	Children’s	Oncology	Group	Trial	AAMLL0531.6	The	SNP	influences	alternative	splicing	at	CD33	exon	2	such	that	the	C	allele	leads	to	expression	of	the	full-length	protein	but	the	T	allele	is	associated	with	increased	levels	of	a	truncated	isoform	lacking	the	external	GO	binding	domain.	The	authors	found	that	only	those	patients	with	a	homozygous	CC	genotype	(approximately	50%	of	patients)	had	a	favorable	response	to	GO,	with	no	clinical	benefit	in	those	with	either	the	heterozygous	CT	or	homozygous	TT	genotype.	The	impact	of	GO	was	greatest	in	the	CC	patients	with	favorable	risk	defined	as	favorable	cytogenetics	or	the	presence	of	NPM1	or	CEBPA	mutations.	These	data	have	important	implications	for	the	use	of	GO	in	AML,	and	are	particularly	pertinent	in	view	of	the	recent	approval	by	the	US	Food	and	Drug	Administration	of	MYLOTARG® for	treatment	of	AML.	We	therefore	investigated	whether	similar	results	pertained	to	younger	adult	patients	treated	on	United	Kingdom	Medical	Research	Council	AML15	(ISRCTN17161961)	and	National	Cancer	Research	Institute	AML17	(ISRCTN55675535)	trials.	Treatment	protocols	and	outcomes	were	as	reported	previously.7,8	Informed	patient	consent	was	obtained	in	accordance	with	the	Declaration	of	Helsinki,	and	ethical	approval	for	tissue	use	from	the	Wales	Research	Ethics	Committee	3.	
	 3		Genomic	DNA	was	available	from	536	of	2063	patients	who	were	entered	into	different	GO	randomizations	in	these	trials,	and	a	flow	chart	of	patients	studied	is	shown	in	Supplemental	Figure	S1.		Of	these,	25	patients	were	randomized	to	receive	GO	in	induction	and	consolidation	and	260	in	induction	alone;	218	were	randomized	to	no-GO	and	33	to	receive	GO	in	consolidation	alone.	The	latter	were	included	in	the	no-GO	group	for	the	analysis	as	there	was	no	evidence	of	a	benefit	for	GO	in	consolidation.7	There	was	no	difference	in	overall	survival	(OS)	between	those	that	were	included	or	not	included	in	our	study	(P=0.06),	nor	between	those	that	were	in	different	trials	(P=0.6).	DNA	was	also	available	from	a	further	184	patients	scheduled	(not	randomized)	to	receive	GO.			Samples	were	screened	for	the	CD33	SNP	using	Hae	III	restriction	enzyme	digestion	of	PCR-generated	amplicons	(See	Supplemental	Data).	Genotype	distribution	was	comparable	to	that	observed	by	Lamba	et	al6:	336	(47%)	were	CC,	319	(44%)	CT	and	65	(9%)	TT,	and	the	minor	allele	frequency	was	30%.	There	were	no	differences	in	baseline	characteristics	between	the	genotypic	groups,	including	age,	sex,	diagnosis	(primary/secondary	disease),	WHO	performance	status,	presenting	white	cell	count	and	cytogenetics	(Supplemental	Table	1).	The	proportion	of	patients	that	received	GO	did	not	differ	significantly	according	to	genotype	(52%	of	CC,	53%	of	CT,	60%	of	TT).	The	expression	level	of	CD33	as	evaluated	by	quantitative	flow	cytometry	of	CD33-positive	blasts	had	previously	been	reported	on	249	of	the	above	patients,5	and	the	median	CD33	mean	fluorescence	intensity	was	10.7	for	CC	genotype	patients	(range,	0.2-298.1),	11.1	for	CT	patients	(range,	0.1-134.8)	and	3.8	for	TT	patients(range,	0.1-13.3)	(P=0.0001	across	all	three	groups)	(Supplemental	Figure	S2).	This	finding	of	a	similar	level	of	expression	in	the	CC	and	CT	groups	but	a	much	lower	level	in	the	TT	group	is	in	accord	with	the	data	of	Lamba	et	al.6		
	 4	In	the	randomized	cohort	of	536	patients,	the	5-year	relapse-free	survival	(RFS)	and	overall	survival	(OS)	were	similar	in	both	arms	(39%	vs	42%	and	46%	vs	47%	for	GO	vs	no-GO	respectively,	both	P=0.9).	There	was,	however	a	strong	trend	to	a	better	outcome	with	GO	in	those	patients	with	favorable	cytogenetics	(hazard	ratio	0.59,	95%	confidence	intervals	0.30-1.14,	P=0.1	for	RFS;	0.47,	0.22-1.01,	P=0.05	for	OS).	This	preferential	impact	of	GO	in	patients	with	favorable	cytogenetics	is	in	agreement	with	previous	publications.1		Amongst	the	randomized	patients	we	found	no	difference	in	response	to	GO	in	the	genotype	groups.	5-year	RFS	for	GO	versus	no-GO	was	36%	versus	42%	for	CC	patients	(P=0.7),	39%	versus	41%	for	CT	(P=0.8)	and	53%	versus	38%	for	TT	(P=0.3)	(Figure	1A).	Similarly,	5-year	OS	was	50%	versus	45%	for	CC	patients	(P=0.3),	40%	versus	50%	for	CT	(P=0.1)	and	56%	versus	40%	for	TT	(P=0.4)	(Figure	1B).	When	the	analysis	was	restricted	to	the	87	patients	with	favorable	cytogenetics,	there	was	again	no	discernible	impact	of	the	genotype	(test	for	heterogeneity	between	subgroups:	Chi	squared	2.0,	P=0.4	for	RFS	and	2.7,	P=0.3	for	OS)	(Figure	2A,B).	In	addition,	there	was	no	difference	in	the	results	according	to	the	dose	of	GO	administered	(3mg/m2	or	6mg/m2,	152	vs	148	patients	respectively)	(Supplemental	Figure	S3).		It	is	difficult	to	explain	why	our	results	should	differ	so	greatly	from	those	of	Lamba	and	colleagues.	The	genotype	frequencies	in	the	two	populations	were	similar,	as	was	the	correlation	between	genotype	and	CD33	expression.	Our	patients	were	adults	(age	range,	13-69	years)	whereas	the	patients	in	the	Children’s	Oncology	Group	Trial	AAMLL0531	were	mainly	children	(0-29	years).	It	is	not	obvious	why	a	difference	in	patient	age	should	have	such	an	impact,	although	one	possibility	is	that	multi-drug	resistance	due	to	P-glycoprotein-mediated	drug	efflux,	which	is	higher	in	older	patients9	and	has	been	reported	to	influence	response	to	GO,10	may	mitigate	against	any	benefit	from	the	CC	genotype	in	adult	patients,	and	
	 5	this	requires	further	investigation.	The	design	of	the	randomized	trials	is	also	different,	with	varying	schedules	and	doses	used	in	the	AML15	and	AML17	trials	investigated	here,	but	a	meta-analysis	of	adult	patients	did	not	suggest	that	these	differences	significantly	impact	outcome.1	Our	study	is	limited	by	its	size	(536	patients	randomized),	but	even	if	the	number	of	patients	were	doubled,	the	chance	of	the	GO	effect	being	significantly	greater	only	in	the	CC	genotype	group	is	less	than	1	in	1000.	Our	findings	are	disappointing	as	the	ability	to	predict	a	response	to	GO	would	have	a	major	impact	on	patient	management	and	would	be	cost-saving.	Further	studies	of	other	randomized	trials	of	GO	addition	to	standard	therapy,	both	in	children	and	in	adults	are	warranted.			 	
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	 9	Figure	legends		Figure	1.	 Outcome	according	CD33	genotype	for	SNP	rs12459419	in	536	patients	randomized	to	receive	or	not	receive	gemtuzumab	ozogamicin	(GO).	(A)	Relapse-free	survival.	(B)	Overall	survival.		Figure	2.	 Stratified	analyses	for	outcome	by	cytogenetic	risk	group	for	patients	in	the	GO	randomization.	GO,	gemtuzumab	ozogamicin;	O-E,	observed-expected;	Var,	variance;	OR,	odds	ratio;	CI,	confidence	intervals.	(A)	Relapse-free	survival.	(B)	Overall	survival.			
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Effect of CD33 biomarker
RFS
 
Cytogenetics
Deaths/Patients
GO No GO
Statistics
(O−E) Var.
O.R. & 95% CI
(GO : No GO)
Favourable:
CC 12/25 8/20 −1·0 4·9 0.82 (0.34, 1.98)
CT 5/18 6/12 −1·7 2·6 0.52 (0.15, 1.74)
TT 1/4 4/4 −1·9 1·2 0.19 (0.03, 1.19)
Subtotal: 18/47 18/36 −4·6 8·7 0.59 (0.30, 1.14)
P = 0·1
Test for heterogeneity between subgroups: χ22 = 2·0; P = 0·4                                                                             
Test for trend between subgroups: χ21 = 1·9; P = 0·2
Intermediate:
CC 42/69 36/58 −1·0 19·2 0.95 (0.61, 1.49)
CT 42/62 37/64 4·2 19·7 1.24 (0.80, 1.93)
TT 8/16 4/7 −0·9 2·3 0.68 (0.19, 2.47)
Subtotal: 92/147 77/129 2·3 41·2 1.06 (0.78, 1.44)
P = 0·7
Test for heterogeneity between subgroups: χ22 = 1·2; P = 0·6                                                                             
Test for trend between subgroups: χ21 = 0·1; P = 0·8
Adverse:
CC 14/14 8/8 −0·7 4·3 0.85 (0.33, 2.19)
CT 13/15 7/8 0·6 4·7 1.15 (0.46, 2.83)
TT 3/4 1/1 −0·8 0·2 0.01 (0.00, 0.90)
Subtotal: 30/33 16/17 −0·9 9·1 0.91 (0.48, 1.74)
P = 0·8
Test for heterogeneity between subgroups: χ22 = 4·1; P = 0·1                                                                             
Test for trend between subgroups: χ21 = 0·1; P = 0·8
Total: 140/227 111/182 −3·1 59·1 0.95 (0.73, 1.22)
0·1 1·0 10·0
GO No GO
better better
Effect P = 0·7
Test for heterogeneity (9 groups): χ28 = 9·8; P = 0·3                                                                                    
Test for trend between subtotals: χ21 = 0·8; P = 0·4
Test for heterogeneity between subtotals: χ22 = 2·5; P = 0·3                                                                             
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Cytogenetics
Deaths/Patients
GO No GO
Statistics
(O−E) Var.
O.R. & 95% CI
(GO : No GO)
Favourable:
CC 7/26 7/22 −0·8 3·4 0.79 (0.27, 2.27)
CT 4/18 6/13 −2·5 2·2 0.33 (0.09, 1.23)
TT 0/4 3/4 −1·6 0·7 0.12 (0.01, 1.12)
Subtotal: 11/48 16/39 −4·9 6·4 0.47 (0.22, 1.01)
P = 0·05
Test for heterogeneity between subgroups: χ22 = 2·7; P = 0·3                                                                             
Test for trend between subgroups: χ21 = 2·6; P = 0·1
Intermediate:
CC 38/75 40/67 −5·4 19·0 0.75 (0.48, 1.18)
CT 46/73 28/67 11·7 18·3 1.90 (1.20, 3.00)
TT 9/18 8/11 −2·6 3·7 0.49 (0.18, 1.38)
Subtotal: 93/166 76/145 3·7 40·9 1.10 (0.81, 1.49)
P = 0·6
Test for heterogeneity between subgroups: χ22 = 10·5; P = 0·005                                                                          
Test for trend between subgroups: χ21 = 1·1; P = 0·3
Adverse:
CC 15/16 14/14 −4·8 5·7 0.43 (0.19, 0.97)
CT 17/19 12/13 0·0 6·9 1.00 (0.48, 2.11)
TT 4/6 1/1 −0·5 0·4 0.31 (0.02, 6.40)
Subtotal: 36/41 27/28 −5·3 13·0 0.67 (0.39, 1.14)
P = 0·1
Test for heterogeneity between subgroups: χ22 = 2·5; P = 0·3                                                                             
Test for trend between subgroups: χ21 = 1·2; P = 0·3
Total: 140/255 119/212 −6·5 60·4 0.90 (0.70, 1.16)
0·1 1·0 10·0
GO No GO
better better
Effect P = 0·4
Test for heterogeneity (9 groups): χ28 = 21·2; P = 0·007                                                                                 
Test for trend between subtotals: χ21 = 0·0; P = 0·9
Test for heterogeneity between subtotals: χ22 = 5·5; P = 0·06                                                                            
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   1	  SUPPLEMENTAL	  DATA	  	  CD33	  SNP	  screening	  PCR	  products	  of	  266bp	  were	  generated	  from	  genomic	  DNA	  using	  BIOTAQ	  DNA	  polymerase	  (Bioline,	  London,	  UK)	  with	  manufacturer’s	  recommended	  conditions	  and	  primers	  CD33	  exon	  1/F	  (5’-­‐CTGGAAGCTGCTTCCTCAGACATG-­‐3’)	  and	  CD33	  exon	  2/D	  (5’-­‐GAACCAGTAACCATGAACTGGGGAGTT-­‐3’)	  at	  an	  annealing	  temperature	  of	  66oC.	  Products	  were	  digested	  overnight	  with	  HaeIII	  (New	  England	  Biolabs,	  Hitchin,	  UK)	  and	  separated	  on	  a	  2%	  agarose	  gel	  to	  discriminate	  between	  the	  C	  alleles	  (94	  +	  29	  +	  143bp)	  and	  T	  alleles	  (94	  +	  172bp).	  	   	  
	   2	  Supplemental	  Table	  1:	  Demographics	  according	  to	  genotype	  for	  the	  CD33	  SNP	  	  Parameter	   Total	  cohort	   CD33	  genotype	  	   P	  CC	  vs	  not	  CC	  	   	   CC	   CT	   TT	   	  Patients	   720	   336	  (47%)	   319	  (44%)	   65	  (9%)	   	  Median	  age,	  years	  	  (range)	   48	  	  (13-­‐69)	   48	  	  (16-­‐69)	   49	  	  (13-­‐68)	   49	  	  (19-­‐63)	   0.3	  Sex:	  	  	  	  	  	  Male	  	  	  	  	  	  Female	   	  395	  (55%)	  325	  (45%)	   	  178	  (53%)	  158	  (47%)	   	  180	  (56%)	  139	  (44%)	   	  37	  (57%)	  28	  	  (43%)	   0.3	  Diagnosis:	  	  	  	  	  	  De	  novo	  	  	  	  	  	  Secondary	  	  	  	  	  	  High	  risk	  MDS	  
	  642	  (89%)	  57	  (8%)	  21	  (3%)	  
	  304	  (90%)	  21	  (6%)	  11	  (3%)	  
	  282	  (88%)	  30	  (9%)	  	  7	  (2%)	  
	  56	  (86%)	  6	  (9%)	  3	  (5%)	  
0.3	  
WHO	  performance	  status:	  	  	  	  	  	  0	  	  	  	  	  	  1	  	  	  	  	  	  2	  	  	  	  	  	  3	  	  	  	  	  	  4	  
	  523	  (73%)	  175	  (24%)	  13	  (2%)	  7	  (1%)	  2	  (<1%)	  
	  235	  (70%)	  90	  (27%)	  7	  (2%)	  5	  (1%)	  2	  (<1%)	  
	  239	  (75%)	  71	  (22%)	  5	  (2%)	  4	  (1%)	  0	  
	  49	  (75%)	  14	  (22%)	  1	  (2%)	  1	  (2%)	  0	  
0.2	  
Median	  WBC,	  x109/L	  	  (range)	   11.3	  	  (0.3-­‐456.0)	   10.2	  (0.8-­‐456.0)	   12.2	  (0.3-­‐430.0)	   16.1	  (0.9-­‐256.3)	   0.3	  Cytogenetics	  (%	  of	  known):	  	  	  	  	  	  Favorable	  	  	  	  	  	  Intermediate	  	  	  	  	  	  Adverse	  	  	  	  	  	  Unknown	  
	  111	  (17%)	  436	  (68%)	  95	  (15%)	  78	  
	  57	  (19%)	  201	  (67%)	  41	  (14%)	  37	  
	  43	  (15%)	  197	  (69%)	  44	  (15%)	  35	  
	  11	  (19%)	  38	  (64%)	  10	  (17%)	  6	  
0.2	  
Median	  MFI	  for	  CD33	  blasts	  (range)	   9.4	  (0.1-­‐298.1)	   10.7	  (0.2-­‐298.1)	   11.1	  (0.1-­‐134.8)	   3.8	  (0.1-­‐13.3)	   0.1	  (0.0001	  across	  all	  groups)	  GO	  given	  No	  GO	  given	   448	  (62%)	  272	  (38%)	   203	  (61%)	  130	  (39%)	   198	  (62%)	  121	  (38%)	   44	  (68%)	  21	  (32%)	   	  	   	   	   	   	   	  Patients	  in	  the	  GO	  vs	  no	  GO	  randomization:	   536	   253	  (47%)	   233	  (43%)	   50	  (9%)	   	  Any	  SCT	  Allogeneic	  SCT	   299	  (56%)	  261	  (49%)	   144	  (57%)	  126	  (50%)	   124	  (53%)	  106	  (45%)	   31	  (62%)	  29	  (58%)	   	  	  Abbreviations:	  MFI,	  mean	  fluorescence	  intensity;	  SCT,	  stem	  cell	  transplant	  	  
Supplemental	Figure	S1.	Flow	chart	of	patients	included	in	the	study.	ADE,	daunorubicin+	
cytarabine+etoposide;	DA,	daunorubicin+cytarabine;	FLAG-Ida,	fludarabine,	cytarabine,	G-CSF,	idarubicin;	GO,	
gemtuzumab ozogamicin;	GO3,	gemtuzumab ozogamicin at	3mg/m2;	GO6,	gemtuzumab ozogamicin at	6mg/m2.
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*Chemotherapy	was	ADE,	DA	or	FLAG-Ida. FLAG-Ida	resulted	in	a	higher	disease-free	survival	(P=0.01)	but	no	
significant	improvement	in	overall	survival	(P=0.2)	(Burnett	et	al,	J	Clin Oncol,	20,	3360-3368,	2013)
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Supplemental	Figure	S2.	CD33	expression	levels	in	CD33-positive	blasts	according	to	the	
patients’	CD33	SNP	genotype.	MFI,	mean	fluorescence	intensity	
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Supplemental	Figure	3.	Overall	survival	according	to	CD33	SNP	genotype	in	
patients	randomized	to	receive	3mg/m2 or	6mg/m2 GO	
